Is Systemic Inflammation of Hemodialysis Patients Improved With the Use of Enalapril? Results of a Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

• DOI: 10.1097/mat.0b013e3181c1d830
• Publication Date: 2010-01-08T08:48:45Z
• Authors: Susan M. Ordaz-Me...; Juana González-Pl...; Fabiola Martín de...; Enrique Rojas-Campos; José L Montañez-F...; Francisco Espinoz...; Alfonso M. Cueto-...
• Keywords: Double blinded

This study compared the effect of enalapril versus placebo on serum tumor necrosis factor (TNF)-α, interleukin (IL)-6, and C-reactive protein (CRP) in hemodialysis a randomized, double- blinded, controlled clinical trial. Patients without infection or antiinflammatory drugs were randomly allocated to (n = 13, enalapril, 20 mg/day) control 12, placebo) group; all had arteriovenous fistula. Serum TNF-α, IL-6, CRP measured at 0, 1, 3 months. Systolic blood pressure (baseline vs. final) was 151 ± 25 135 19 mm Hg (p < 0.05) group 154 21 144 27 diastolic 86 9 76 13 91 16 81 18 Hg, respectively; median (percentiles 25%–75%) IL-6 4.2 (3–8) 4.1 (2–9) pg/mL 6.3 (3–9) 6.7 pg/mL; 1.9 (1–7) 3.0 (1–12) mg/L 4.7 (1–16) 3.9 (2–16) mg/L, respectively. TNF-α detected only two patients. Enalapril significantly reduced patients, but it did not decrease with placebo.